8-K Announcements
6Material company update
Feb 13, 2026·SEC
Material company update
Jan 12, 2026·SEC
Material company update
Nov 13, 2025·SEC
Orchestra BioMed Holdings, Inc.(OBIO)Earnings, Financials & Key Ratios
OBIO•NASDAQ
$4.24
Price updated Jun 27, 2026
AboutOrchestra BioMed Holdings, Inc. operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension; and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold retractors that are minimally invasive surgical device solutions. The company has a strategic collaboration with Medtronic for the development and commercialization of BackBeat CNT for the treatment of hypertension in pacemaker-indicated patients; and a strategic partnership with Terumo Corporation for the development and commercialization of Virtue SAB for the treatment of artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.Show more
- Revenue$33M+1169.2%
- EBITDA-$51M+19.6%
- Net Income-$53M+13.6%
- EPS (Diluted)-1.38+16.9%
- Gross Margin99.43%+7.8%
- EBITDA Margin-153.75%+93.7%
- Operating Margin-154.73%+93.7%
- Net Margin-157.4%+93.2%
- ROE-109.41%+9.5%
OBIO Price & Volume
Orchestra BioMed Holdings, Inc. (OBIO) stock price & volume — 10-year historical chart
Loading chart...
Milestone Dependency Masks Persistent Operational Cash Burn
Investment Thesis • Updated 2026Q1
VerdictNegative
Growth:Mixed
Profitability:Negative
Financial:Vulnerable
Cash Flow:Burning
Primary Risk:Milestone-dependent liquidity exhaustion
Key Thesis Takeaways
- Orchestra BioMed remains in a high-risk, pre-commercial development phase where financial performance is tethered to volatile, milestone-driven revenue rather than sustainable product sales.
- While the company maintains high gross margins exceeding 94% in most quarters, the lack of recurring revenue and consistent quarterly operating losses—such as the $22.1M loss in 2026Q1—necessitate ongoing external financing.
- Investors should monitor the company's ability to secure new licensing agreements, as the exhaustion of deferred revenue, which fell from $17.4M in 2023Q4 to $0 in 2026Q1, leaves the balance sheet vulnerable to liquidity shocks.
Verdict Logic
the company's reliance on sporadic milestone payments and the $22.1M operating loss reported in 2026Q1 suggest a precarious liquidity profile that lacks a clear path to self-sustaining commercial profitability.
OBIO Growth Metrics
Orchestra BioMed Holdings, Inc. (OBIO) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years42.48%
3 Years111.62%
TTM1033.89%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM17.61%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM19.77%
Return on Capital
10 Years-92.59%
5 Years-95.31%
3 Years-72.95%
Last Year-65.54%
OBIO Recent Earnings
Orchestra BioMed Holdings, Inc. (OBIO) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 9/12 qtrs (75%)●Beat Revenue 5/12 qtrs (45%)
Q2 2026Latest
May 12, 2026Metric
Actual
Est
EPS
$0.33+17.5%
$0.40
Rev
$110,000-88.0%
$918,714
Q2 2026
Mar 12, 2026Metric
Actual
Est
EPS
$0.26+168.4%
$0.38
Rev
$31M+3220.8%
$931,000
Q4 2025
Nov 10, 2025Metric
Actual
Est
EPS
$0.40-5.3%
$0.38
Rev
$861,000+16.1%
$741,400
Q3 2025
Aug 12, 2025Metric
Actual
Est
EPS
$0.50+2.0%
$0.51
Rev
$836,000+7.3%
$778,833
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 12, 2026 | $0.33vs $0.40+17.5% | $110,000vs $918,714-88.0% |
| Q2 2026 | Mar 12, 2026 | $0.26vs $0.38+168.4% | $31Mvs $931,000+3220.8% |
| Q4 2025 | Nov 10, 2025 | $0.40vs $0.38-5.3% | $861,000vs $741,400+16.1% |
| Q3 2025 | Aug 12, 2025 | $0.50vs $0.51+2.0% | $836,000vs $778,833+7.3% |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Orchestra BioMed Holdings, Inc. (OBIO)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $4.24 | $253.89M | -3.07 | 1169.22% | -157.4% | -109.41% | — | |
| $15.43 | $1.76B | -12.65 | 8.28% | -25.66% | -50.82% | — | |
| $0.42 | $58.92M | 14.00 | 14.21% | 1.5% | 3.68% | — | |
| $44.23 | $65.74B | 22.80 | 19.87% | 17.23% | 14.67% | — | |
| $80.98 | $103.97B | 21.71 | 8.43% | 13.2% | 9.78% | — | |
| $93.82 | $163.42B | 25.22 | 5.67% | 13.91% | 12.09% | — |
Compare OBIO vs Peers
Orchestra BioMed Holdings, Inc. (OBIO) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
OBIO SEC Filings & Documents
Orchestra BioMed Holdings, Inc. (OBIO) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when OBIO posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
OBIO Frequently Asked Questions
Orchestra BioMed Holdings, Inc. (OBIO) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Orchestra BioMed Holdings, Inc.'s revenue?
Orchestra BioMed Holdings, Inc. (OBIO) reported $32.7M in revenue for fiscal year 2025. This represents a 474% increase from $5.7M in 2020.
How fast is Orchestra BioMed Holdings, Inc. growing?
Orchestra BioMed Holdings, Inc. (OBIO) grew revenue by 1169.2% over the past year. This is strong growth.
Is OBIO profitable?
Orchestra BioMed Holdings, Inc. (OBIO) reported a net loss of $54.6M for fiscal year 2025.
Dividend & Returns
What is OBIO's return on equity?
Orchestra BioMed Holdings, Inc. (OBIO) has a return on equity (ROE) of -109.4%. Negative ROE indicates the company is unprofitable.
What is Orchestra BioMed Holdings, Inc.'s free cash flow?
Orchestra BioMed Holdings, Inc. (OBIO) had negative free cash flow of $55.1M in fiscal year 2025, likely due to heavy capital investments.